In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
Recent updates in endocrinology reveal fezolinetant as a promising non-hormonal treatment for menopausal symptoms and tirzepatide’s impressive 93% risk reduction in progression from prediabetes to type 2...
Recent updates in endocrinology reveal fezolinetant as a promising non-hormonal treatment for menopausal symptoms and tirzepatide’s impressive 93% risk reduction in progression from prediabetes to type 2...
